Profoundbio Announces Completion Of $70 Million Series A+ Financing To Advance Antibody-Drug Conjugate (Adc) Programs Into The Clinic
Profoundbio Announces Completion Of $70 Million Series A+ Financing To Advance Antibody-Drug Conjugate (Adc) Programs Into The Clinic
06/02/22, 8:00 AM
Location
woodinvilleMoney raised
$70 million
Round Type
series a
ProfoundBio, a biotech company focusing on the development of novel targeted therapies, announced the closing of a $70 million Series A+ financing round led by Sequoia China. Current investors Lilly Asia Venture, Oriza, Chang'an Capital, LYFE Capital, and K2VC also participated in this round of financing. ProfoundBio has raised a total of more than $138 million in the past two years. Following the closing, Lynn Yang from Sequoia China will be joining the company's Board of Directors.
Company Info
Location
woodinville, washington, united states
Additional Info
ProfoundBio is an oncology biotherapeutics company focused on the development of novel antibody-based therapeutics with curative potential for patients with cancer. Built on innovative technology platforms, ProfoundBio has developed a pipeline consisting of multiple solid tumor-targeting drug candidates that are currently in discovery and preclinical development stages. ProfoundBio has operations in both the greater Seattle area, WA, USA and Suzhou, China.
For more information, please visit www.profoundbio.com.